Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNT1 | O60563 | 4/20 | 0.42 |
| ▸ | CDK9 | P50750 | 4/20 | 0.42 |
| ▸ | CCND1 | P24385 | 12/20 | 0.41 |
| ▸ | CDK2 | P24941 | 10/20 | 0.41 |
| ▸ | CCNE1 | P24864 | 9/20 | 0.41 |
| ▸ | CDK6 | Q00534 | 8/20 | 0.41 |
| ▸ | CDK4 | P11802 | 6/20 | 0.41 |
| ▸ | CCND3 | P30281 | 1/20 | 0.41 |
| ▸ | CTSS | P25774 | 2/20 | 0.40 |
| ▸ | CTSK | P43235 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.37 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19711675 | 0.84 | CCND1 (0.40) | CCNT1CDK9CCND1CDK2CCNE1 | |
| SCHEMBL20676931 | 0.82 | CCND1 (0.42) | CCNT1CDK9CCND1CDK2CCNE1 | |
| SCHEMBL6363390 | 0.81 | CTSK (0.48) | CCNT1CDK9CCND1CDK2CCNE1 | |
| SCHEMBL27927200 | 0.81 | NUAK1 (0.40) | CCNT1CDK9CCND1CDK2CCNE1 | |
| SCHEMBL31475403 | 0.79 | CDK2 (0.57) | CCNT1CDK9CCND1CDK2CCNE1 | |
| SCHEMBL20677055 | 0.79 | CDK6 (0.52) | CCNT1CDK9CCND1CDK2CCNE1 | |
| SCHEMBL19711678 | 0.79 | CDK4 (0.51) | CCNT1CDK9CCND1CDK2CCNE1 | |
| SCHEMBL2685547 | 0.78 | CTSK (0.48) | CCNT1CDK9CCND1CDK2CCNE1 | |
| SCHEMBL1991037 | 0.78 | CTSK (0.48) | CCNT1CDK9CCND1CDK2CCNE1 | |
| SCHEMBL1993255 | 0.78 | CTSK (0.41) | CCNT1CDK9CCND1CDK2CCNE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024056090-A1 | PYRROLOPYRIMIDINE DERIVATIVE AS RSK INHIBITOR AND USE THEREOF | 华东师范大学 | 2024-03-21 | — | — | WO | disclosed |
| CN-117720532-A | Pyrrolopyrimidine derivatives as RSK inhibitors and use thereof | 华东师范大学 | 2024-03-19 | — | — | CN | disclosed |
| CN-111386272-B | Improved preparation method of Riboxib and salt thereof | 费森尤斯卡比肿瘤学有限公司 | 2023-01-06 | — | — | CN | disclosed |
| US-20200277295-A1 | AN IMPROVED PROCESS FOR THE PREPARATION OF RIBOCICLIB AND ITS SALTS | FRESENIUS KABI ONCOLOGY LIMITED (IN) | 2020-09-03 | — | — | US | disclosed |
| EP-3700908-A1 | AN IMPROVED PROCESS FOR THE PREPARATION OF RIBOCICLIB AND ITS SALTS | Fresenius Kabi Oncology Ltd (IN) | 2020-09-02 | — | — | EP | disclosed |
| CN-111386272-A | Improved preparation method of Riboxib and salt thereof | 费森尤斯卡比肿瘤学有限公司 | 2020-07-07 | — | — | CN | disclosed |
| CN-107936029-B | Method for synthesizing Ribociclib | 南京奇可药业有限公司 | 2020-06-30 | — | — | CN | disclosed |
| US-8324225-B2 | Pyrrolopyrimidine compounds and their uses | NOVARTIS AG (CH) | 2012-12-04 | — | — | US | disclosed |
| US-20120207763-A1 | PYRROLOPYRIMIDINE COMPOUNDS AND THEIR USES | ASTEX THERAPEUTICS LIMITED (GB) | 2012-08-16 | — | — | US | disclosed |
| US-20090318441-A1 | Pyrrolopyrimidine Compounds and Their Uses | ASTEX THERAPEUTICS LTD. | 2009-12-24 | — | — | US | disclosed |
| CN-101594871-A | Pyrrolopyrimidine compounds and uses thereof | NOVARTIS AG (CH) | 2009-12-02 | — | — | CN | disclosed |
| EP-2029145-A2 | PYRROLOPYRIMIDINE COMPOUNDS AND THEIR USES | Novartis Ag (CH) | 2009-03-04 | — | — | EP | disclosed |
| WO-2007140222-A2 | PYRROLOPYRIMIDINE COMPOUNDS AND THEIR USES | NOVARTIS AG (CH) | 2007-12-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090318441-A1 | Pyrrolopyrimidine Compounds and Their Uses | PRKDC, TK2, PNKP | CCNT1 455/4885CDK9 71/4885CCND1 615/4885 |
| US-20200277295-A1 | AN IMPROVED PROCESS FOR THE PREPARATION OF RIBOCICLIB AND ITS SALTS | SUCLG2, RRM2B, IDH1 | CCNT1 318/4885CDK9 198/4885CCND1 565/4885 |
| US-20120207763-A1 | PYRROLOPYRIMIDINE COMPOUNDS AND THEIR USES | PRKDC, TK2, PNKP | CCNT1 455/4885CDK9 71/4885CCND1 615/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.